Market Research Report: Cresset

Company Overview

• Name: Cresset

• Mission of the Company: Cresset aims to increase the chance of success in discovering new and better molecules by delivering solutions that optimize chemistry R&D innovation and efficiency. Their mission is to enable customers to accelerate the development of better treatments to improve the health of humans, animals, and the environment.

• Founded: The company was founded in 2002 by Dr. Andy Vinter.

• Key People:

• Dr. Andy Vinter (1943 - 2019): Founder, known for his research on comparing molecules based on their electrostatic potentials and developing the XED force field.

• Tim Cheeseright: Current CEO (as of end of 2024).

• Rob Scoffin: Former CEO, now President.

• Phil Hastings: Current Chief Commercial Officer.

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue of the Company: No information is available.

• Known For: Cresset is known for its state-of-the-art in silico discovery solutions, providing expert software and contract research services to computational, medicinal, and synthetic chemists to make better molecule design decisions.

Products

1. Flare™

• Description: It combines modern visualization and analysis tools into a single workflow.

• Key Features: Flare incorporates Spark technology to improve workflows by combining Spark, machine learning, and FEP (Free Energy Perturbation) to generate novel and active molecules efficiently.

2. Spark™

• Description: A software tool for scaffold hopping and R-group exploration that provides insights into the calculated ideal shape and motivation space for a given interaction.

• Key Features: Integrated into the Flare application to enable combined workflows.

3. Blaze™

• Description: A virtual screening platform used in drug discovery projects.

• Key Features: It identifies hit compounds using virtual screening, such as optimizing insulin-regulated aminopeptidase inhibitors.

4. Torx®

• Description: A DMTA (Design-Make-Test-Analyze) platform.

• Key Features: Facilitates collaboration across chemistry teams, accelerating the cycle from design to data, with enhanced visualization when tracking molecules through synthesis.

Recent Developments

• SOC 2 Compliance: Cresset achieved SOC 2 Type 1 compliance, demonstrating a commitment to data security and protecting customer data by meeting rigorous standards for security, availability, integrity, confidentiality, and privacy.

• AI Investments: In 2024, the company invested in Gen-AI technologies including large language models to enhance the user experience in their software, developing early versions of chatbots to assist with queries, automate code writing, and simplify drug design tasks.

• Product Integrations and Enhancements:

• Integration of Spark technology into Flare™ to facilitate combined workflows.

• Development of generative chemistry applications using Cresset’s unique electrostatic and shape methods, anticipated to be added in 2025.

• Leadership Changes:

• Rob Scoffin transitioned to President after 14 years as CEO.

• Phil Hastings joined as Chief Commercial Officer and David Bardsley retired after contributing 12 years of growth.

• Partnerships and Collaborations:

• Collaborations with Elixir Software on Torx®, BASF Crop Protection, BioMolTech, and various other partners across multiple domains such as agrochemicals, protein-ligand software, and computational chemistry.

Events and Conferences

• Upcoming Workshops and Conferences:

• BioAsia 2025 in Hyderabad, India.

• 2nd Conformational Design in Drug Discovery, Cambridge, UK.

• AI in Drug Discovery event, London, UK.

• Free Energy Methods in Drug Design workshop in Boston, MA.

This detailed review of Cresset outlines its strategic direction, innovative software solutions, key partnerships, and a significant focus on integrating advanced AI technologies to maintain its legacy as a leader in computational chemistry solutions.